

|   |   |                          |
|---|---|--------------------------|
| Drug resistance interpretation: PR  |   | HIVDB 9.5.1 (2023-11-05) |
| PI Major Mutations:   | None  |                          |
| PI Accessory Mutations:   | None  |                          |
| PR Other Mutations:   | V11H • T12V • I13R • K14L • I15N • G16R • Q18K • K20R • M36I • R41K • L63P • H69K • L89M • I93L |                          |
| Protease Inhibitors   |   |                          |
| atazanavir/r (ATV/r)  | Susceptible   |                          |
| darunavir/r (DRV/r)   | Susceptible   |                          |
| fosamprenavir/r (FPV/r)   | Susceptible   |                          |
| indinavir/r (IDV/r)   | Susceptible   |                          |
| lopinavir/r (LPV/r)   | Susceptible   |                          |
| nelfinavir (NFV)  | Susceptible   |                          |
| saquinavir/r (SQV/r)  | Susceptible   |                          |
| tipranavir/r (TPV/r)  | Susceptible   |                          |
| PR comments   |   |                          |
| Other   |   |                          |
| <ul style="list-style-type: none"><li>K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.</li></ul> |   |                          |

|                      |                          |
|----------------------|--------------------------|
| Mutation scoring: PR | HIVDB 9.5.1 (2023-11-05) |
|----------------------|--------------------------|

No drug resistance mutations were found for PI.

|                                    |                          |
|------------------------------------|--------------------------|
| Drug resistance interpretation: RT | HIVDB 9.5.1 (2023-11-05) |
|------------------------------------|--------------------------|

|                     |  |
|---------------------|--|
| NRTI Mutations:     | D67N • K70E • M184V • T215I  |
| NNRTI Mutations:    | V179D • Y188L  |
| RT Other Mutations: | E6D • V35T • T39E • V90I • K103R • K122E • D123G • P176S • D177E • T200A • Q207E • R211K • P217S • P226S • P236S • K238Q • I244Y • V245T • L246A • P247A • E248D • D250E • N255H • I257L • A267X • A272P |

|   |                         |   |                       |
|---|-------------------------|---|-----------------------|
| Nucleoside Reverse Transcriptase Inhibitors |                         | Non-nucleoside Reverse Transcriptase Inhibitors |                       |
| abacavir (ABC)                              | Intermediate Resistance | doravirine (DOR)                                | High-Level Resistance |
| zidovudine (AZT)                            | Low-Level Resistance    | efavirenz (EFV)                                 | High-Level Resistance |
| stavudine (D4T)                             | Intermediate Resistance | etravirine (ETR)                                | Low-Level Resistance  |
| didanosine (DDI)                            | Intermediate Resistance | nevirapine (NVP)                                | High-Level Resistance |
| emtricitabine (FTC)                         | High-Level Resistance   | rilpivirine (RPV)                               | High-Level Resistance |
| lamivudine (3TC)                            | High-Level Resistance   |   |                       |
| tenofovir (TDF)                             | Low-Level Resistance    |   |                       |

RT comments

NRTI

- **D67N** is a non-polymorphic TAM associated with low-level resistance to AZT.
- **K70/E/Q/N/T/S/G** cause low-leve resistance to ABC and TDF.
- **M184V/I** cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). **M184V/I** are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.
- T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF. **T215S/C/D/E/I/V/N/A/L** do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once been infected with a virus containing T215Y/F.

NNRTI

- **V179D/E** are somewhat polymorphic accessory NNRTI-selected mutation. In combination with other NNRTI DRMs, they appear to contribute low-levels of reduced susceptibility to each of the NNRTIs. In particular, the combinations of K103R/**V179D** and V106I/**V179D** act synergistically to reduce NVP and EFV susceptibility.
- **Y188L** is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.

Other

- **V90I** is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility.
- **K103R** is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.
- P236L is a rare mutation selected commonly by DLV, which appears to have little if any effect on current NNRTIs. **P236S** is a highly unusual mutation at this position.
- K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal effects on NNRTI susceptibility. **K238Q** is a highly unusual mutation at this position.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI:

Download CSV



| Rule                         | ABC ⇅ | AZT ⇅ | D4T ⇅ | DDI ⇅ | FTC ⇅ | 3TC ⇅ | TDF ⇅ |
|------------------------------|-------|-------|-------|-------|-------|-------|-------|
| <a href="#">D67N</a>         | 5     | 15    | 15    | 5     | 0     | 0     | 5     |
| <a href="#">K70E</a>         | 15    | 0     | 15    | 15    | 10    | 10    | 15    |
| <a href="#">M184V</a>        | 15    | -10   | -10   | 10    | 60    | 60    | -10   |
| <a href="#">T215I</a>        | 5     | 20    | 20    | 10    | 0     | 0     | 5     |
| <a href="#">K70E + M184V</a> | 0     | 0     | 10    | 0     | 0     | 0     | 10    |
| Total                        | 40    | 25    | 50    | 40    | 70    | 70    | 25    |

Drug resistance mutation scores of NNRTI:

Download CSV



| Rule                          | DOR ⇅ | EFV ⇅ | ETR ⇅ | NVP ⇅ | RPV ⇅ |
|-------------------------------|-------|-------|-------|-------|-------|
| <a href="#">Y188L</a>         | 60    | 60    | 10    | 60    | 60    |
| <a href="#">K103R + V179D</a> | 0     | 20    | 0     | 20    | 15    |
| <a href="#">V179D</a>         | 0     | 10    | 10    | 10    | 10    |
| Total                         | 60    | 90    | 20    | 90    | 85    |